| NCT03304288 |
The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT03304288 |
Recruiting |
Peking University People’s Hospital |
2020-08-31 |
| NCT03275740 |
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 |
https://ClinicalTrials.gov/show/NCT03275740 |
Recruiting |
Pfizer |
2020-10-21 |
| NCT03275454 |
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT03275454 |
Recruiting |
Sanofi |
2022-05-31 |
| NCT03258866 |
The Study of Different Dose Rituximab in the Treatment of ITP |
https://ClinicalTrials.gov/show/NCT03258866 |
Completed |
Shandong University |
2015-12-31 |
| NCT03229746 |
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT03229746 |
Completed |
Assiut University |
2018-06-01 |
| NCT03222843 |
Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient |
https://ClinicalTrials.gov/show/NCT03222843 |
Recruiting |
Jiangsu HengRui Medicine Co., Ltd. |
2020-06-30 |
| NCT03201848 |
The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT03201848 |
Recruiting |
Qidong Gaitianli Medicines Co., Ltd |
2021-12-31 |
| NCT03177629 |
H. Pylori Eradication for Moderate ITP |
https://ClinicalTrials.gov/show/NCT03177629 |
Recruiting |
Seoul National University Hospital |
2020-06-30 |
| NCT03172676 |
Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT03172676 |
Recruiting |
Assiut University |
2020-06-01 |
| NCT03156452 |
Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate |
https://ClinicalTrials.gov/show/NCT03156452 |
Active, not recruiting |
University Hospitals Bristol NHS Foundation Trust |
2020-02-13 |
| NCT03154385 |
Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT03154385 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2019-11-13 |
| NCT03102593 |
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP |
https://ClinicalTrials.gov/show/NCT03102593 |
Completed |
argenx BVBA |
2019-04-09 |
| NCT02287649 |
Polymorphism and Auto-reactive B and T Cells Subsets in Adult’s Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT02287649 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2015-10-02 |
| NCT03010202 |
The PROLONG Trial - Rituximab Maintenance Therapy in ITP |
https://ClinicalTrials.gov/show/NCT03010202 |
Recruiting |
Ostfold Hospital Trust |
2023-12-31 |
| NCT02914054 |
Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone |
https://ClinicalTrials.gov/show/NCT02914054 |
Completed |
Isfahan University of Medical Sciences |
2017-09-15 |
| NCT02868099 |
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT02868099 |
Completed |
Kyowa Hakko Kirin China Pharmaceutical Co., LTD. |
2017-02-28 |
| NCT02868060 |
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT02868060 |
Completed |
Kyowa Hakko Kirin China Pharmaceutical Co., LTD. |
2017-08-31 |
| NCT02859909 |
This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT02859909 |
Completed |
Biotest |
2018-12-31 |
| NCT02760251 |
Immunomodulation With Romiplostim in Young Adults With ITP |
https://ClinicalTrials.gov/show/NCT02760251 |
Completed |
University Hospital, Basel, Switzerland |
2019-07-31 |
| NCT02718716 |
Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT02718716 |
Completed |
UCB Pharma |
2019-02-28 |
| NCT03395210 |
A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT03395210 |
Recruiting |
Principia Biopharma Inc. |
2021-06-30 |
| NCT02402998 |
Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia |
https://ClinicalTrials.gov/show/NCT02402998 |
Active, not recruiting |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2018-05-22 |
| NCT02391272 |
A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy |
https://ClinicalTrials.gov/show/NCT02391272 |
Completed |
Shandong University |
2015-11-30 |
| NCT02351622 |
Caffeic Acid Tablets as a Second-line Therapy for ITP |
https://ClinicalTrials.gov/show/NCT02351622 |
Completed |
Shandong University |
2013-12-31 |
| NCT02334813 |
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT02334813 |
Completed |
University Hospital, Essen |
2015-01-31 |
| NCT02281370 |
Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT02281370 |
Completed |
GlaxoSmithKline |
2014-12-24 |
| NCT02279173 |
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT02279173 |
Completed |
Amgen |
2018-08-30 |
| NCT02273960 |
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP |
https://ClinicalTrials.gov/show/NCT02273960 |
Completed |
Bristol-Myers Squibb |
2018-01-22 |
| NCT02201290 |
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT02201290 |
Completed |
Novartis |
2017-07-04 |
| NCT02153060 |
An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT02153060 |
Completed |
Shandong University |
2015-01-31 |
| NCT02139501 |
An Investigation of rhTPO With Different Frequencies in the Management of ITP |
https://ClinicalTrials.gov/show/NCT02139501 |
Completed |
Shandong University |
2015-01-31 |
| NCT02077192 |
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT02077192 |
Active, not recruiting |
Rigel Pharmaceuticals |
2020-03-31 |
| NCT02076412 |
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT02076412 |
Completed |
Rigel Pharmaceuticals |
2016-08-31 |
| NCT02076399 |
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT02076399 |
Completed |
Rigel Pharmaceuticals |
2016-04-21 |
| NCT02063789 |
An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT02063789 |
Completed |
Green Cross Corporation |
2016-04-30 |
| NCT01289509 |
A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects |
https://ClinicalTrials.gov/show/NCT01289509 |
Completed |
Eisai Inc. |
2011-03-31 |
| NCT04274452 |
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT04274452 |
Recruiting |
argenx BVBA |
2021-09-01 |
| NCT01988506 |
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases |
https://ClinicalTrials.gov/show/NCT01988506 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2020-08-13 |
| NCT01963260 |
Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) |
https://ClinicalTrials.gov/show/NCT01963260 |
Completed |
Merck Sharp & Dohme Corp. |
2015-04-26 |
| NCT01880047 |
Safety and Efficacy of Eltrombopag at Escalated Doses |
https://ClinicalTrials.gov/show/NCT01880047 |
Completed |
Weill Medical College of Cornell University |
2017-02-15 |
| NCT01762761 |
Eltrombopag Phase III Study In Chinese Chronic ITP Patients |
https://ClinicalTrials.gov/show/NCT01762761 |
Completed |
Novartis |
2014-06-05 |
| NCT01734044 |
rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP |
https://ClinicalTrials.gov/show/NCT01734044 |
Completed |
Shandong University |
2014-07-31 |
| NCT01730352 |
Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients |
https://ClinicalTrials.gov/show/NCT01730352 |
Completed |
Federal University of São Paulo |
2011-05-31 |
| NCT01719692 |
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT01719692 |
Completed |
Institute of Hematology & Blood Diseases Hospital |
2015-10-31 |
| NCT01713855 |
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT01713855 |
Completed |
Neufeld, Ellis J, MD, PhD |
NA |
| NCT01713738 |
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT01713738 |
Completed |
Neufeld, Ellis J, MD, PhD |
2005-12-31 |
| NCT01667263 |
The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT01667263 |
Completed |
Peking University People’s Hospital |
2016-07-01 |
| NCT01652599 |
Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT |
https://ClinicalTrials.gov/show/NCT01652599 |
Completed |
Hospital Universitario Dr. Jose E. Gonzalez |
2013-06-30 |
| NCT01621204 |
A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients |
https://ClinicalTrials.gov/show/NCT01621204 |
Completed |
McMaster University |
2019-06-30 |
| NCT01610180 |
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) |
https://ClinicalTrials.gov/show/NCT01610180 |
Completed |
Fondazione Progetto Ematologia |
2018-06-30 |
| NCT01568333 |
A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT01568333 |
Completed |
Shandong University |
2017-10-31 |
| NCT01549054 |
A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 |
https://ClinicalTrials.gov/show/NCT01549054 |
Completed |
Eisai Inc. |
2012-06-30 |
| NCT01525836 |
rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP |
https://ClinicalTrials.gov/show/NCT01525836 |
Completed |
Shandong University |
2013-12-31 |
| NCT01520909 |
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. |
https://ClinicalTrials.gov/show/NCT01520909 |
Completed |
GlaxoSmithKline |
2014-01-31 |
| NCT01506414 |
Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT01506414 |
Completed |
Shandong University |
2013-08-31 |
| NCT01444417 |
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients |
https://ClinicalTrials.gov/show/NCT01444417 |
Completed |
Amgen |
2015-02-28 |
| NCT01438840 |
Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) |
https://ClinicalTrials.gov/show/NCT01438840 |
Completed |
Eisai Inc. |
2013-11-30 |
| NCT01437384 |
Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. |
https://ClinicalTrials.gov/show/NCT01437384 |
Completed |
Eisai Inc. |
2012-03-31 |
| NCT01390649 |
A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT01390649 |
Completed |
CSL Behring |
2014-09-30 |
| NCT01356511 |
High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT01356511 |
Completed |
Shandong University |
2014-05-31 |
| NCT01327872 |
Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects |
https://ClinicalTrials.gov/show/NCT01327872 |
Completed |
Eisai Inc. |
2011-04-30 |
| NCT04368598 |
The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed ITP |
https://ClinicalTrials.gov/show/NCT04368598 |
Recruiting |
Peking University People’s Hospital |
2020-12-31 |
| NCT04224688 |
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT04224688 |
Recruiting |
UCB Pharma |
2022-07-31 |
| NCT04217148 |
The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT04217148 |
Recruiting |
Peking University People’s Hospital |
2022-12-31 |
| NCT04132050 |
A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 |
https://ClinicalTrials.gov/show/NCT04132050 |
Recruiting |
Kissei Pharmaceutical Co., Ltd. |
2021-12-31 |
| NCT04089267 |
Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT04089267 |
Completed |
Shenyang Sunshine Pharmaceutical Co., LTD. |
2018-12-31 |
| NCT04083014 |
Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia |
https://ClinicalTrials.gov/show/NCT04083014 |
Recruiting |
Peking Union Medical College Hospital |
2022-08-20 |
| NCT04056195 |
Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT04056195 |
Recruiting |
Oscotec Inc. |
2021-02-28 |
| NCT04039477 |
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP |
https://ClinicalTrials.gov/show/NCT04039477 |
Recruiting |
Kezar Life Sciences, Inc. |
2020-12-31 |
| NCT04014413 |
Safety and Efficacy of Fecal Microbiota Transplantation |
https://ClinicalTrials.gov/show/NCT04014413 |
Recruiting |
Chinese University of Hong Kong |
2023-10-31 |
| NCT04014166 |
Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT04014166 |
Recruiting |
Institute of Hematology & Blood Diseases Hospital |
2021-12-31 |
| NCT03951623 |
The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients |
https://ClinicalTrials.gov/show/NCT03951623 |
Recruiting |
Hutchison Medipharma Limited |
2021-12-31 |
| NCT03939637 |
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children |
https://ClinicalTrials.gov/show/NCT03939637 |
Recruiting |
Baylor College of Medicine |
2022-05-01 |
| NCT03866798 |
Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT03866798 |
Recruiting |
Octapharma |
2022-03-31 |
| NCT03866577 |
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients |
https://ClinicalTrials.gov/show/NCT03866577 |
Recruiting |
Momenta Pharmaceuticals, Inc. |
2022-04-30 |
| NCT03830749 |
Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT03830749 |
Recruiting |
Humanity & Health Medical Group Limited |
2020-12-31 |
| NCT03771378 |
Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT03771378 |
Recruiting |
Wuhan Union Hospital, China |
2020-05-01 |
| NCT03692754 |
Atorvastatin in Management of Newly Diagnosed ITP |
https://ClinicalTrials.gov/show/NCT03692754 |
Recruiting |
Shandong University |
2021-12-01 |
| NCT03603132 |
A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics |
https://ClinicalTrials.gov/show/NCT03603132 |
Completed |
Jiangsu HengRui Medicine Co., Ltd. |
2018-08-17 |
| NCT03524612 |
A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP |
https://ClinicalTrials.gov/show/NCT03524612 |
Recruiting |
Novartis |
2022-06-30 |
| NCT03421184 |
Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus |
https://ClinicalTrials.gov/show/NCT03421184 |
Recruiting |
University Hospital, Bordeaux |
2020-11-30 |
| NCT03412188 |
The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP. |
https://ClinicalTrials.gov/show/NCT03412188 |
Recruiting |
Ain Shams University |
2019-11-30 |
| NCT01129024 |
An Open-label Safety Study of S-888711 |
https://ClinicalTrials.gov/show/NCT01129024 |
Completed |
Shionogi Inc. |
2011-08-31 |
| NCT01107951 |
Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP |
https://ClinicalTrials.gov/show/NCT01107951 |
Completed |
Hospital Universitario Dr. Jose E. Gonzalez |
2010-04-30 |
| NCT01098487 |
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT01098487 |
Completed |
GlaxoSmithKline |
2014-05-31 |
| NCT01072162 |
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect |
https://ClinicalTrials.gov/show/NCT01072162 |
Completed |
GlaxoSmithKline |
2010-04-07 |
| NCT01071954 |
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura |
https://ClinicalTrials.gov/show/NCT01071954 |
Completed |
Amgen |
2017-01-12 |
| NCT00909077 |
The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00909077 |
Completed |
Copenhagen University Hospital at Herlev |
2012-06-01 |
| NCT00908037 |
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00908037 |
Completed |
GlaxoSmithKline |
2014-02-01 |
| NCT00907478 |
Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00907478 |
Completed |
Amgen |
2014-01-09 |
| NCT00902018 |
Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00902018 |
Completed |
Weill Medical College of Cornell University |
2015-09-07 |
| NCT00888901 |
Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag |
https://ClinicalTrials.gov/show/NCT00888901 |
Completed |
Medical University of Vienna |
2011-03-31 |
| NCT00860600 |
Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients |
https://ClinicalTrials.gov/show/NCT00860600 |
Completed |
PhytoHealth Corporation |
2011-08-31 |
| NCT04200456 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) |
https://ClinicalTrials.gov/show/NCT04200456 |
Recruiting |
UCB Pharma |
2021-12-31 |
| NCT00828750 |
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00828750 |
Completed |
GlaxoSmithKline |
2011-02-28 |
| NCT01349790 |
Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT01349790 |
Completed |
Octapharma |
2013-07-31 |
| NCT04070599 |
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura. |
https://ClinicalTrials.gov/show/NCT04070599 |
Completed |
University Hospital, Bordeaux |
2014-03-05 |
| NCT03998982 |
Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP |
https://ClinicalTrials.gov/show/NCT03998982 |
Recruiting |
Shandong University |
2020-04-01 |
| NCT04225156 |
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). |
https://ClinicalTrials.gov/show/NCT04225156 |
Recruiting |
argenx BVBA |
2022-06-30 |
| NCT04188379 |
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). |
https://ClinicalTrials.gov/show/NCT04188379 |
Recruiting |
argenx BVBA |
2021-06-06 |
| NCT02556814 |
Caffeic Acid Combining High-dose Dexamethasone in Management of ITP |
https://ClinicalTrials.gov/show/NCT02556814 |
Completed |
Shandong University |
2018-03-31 |
| NCT01143038 |
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim |
https://ClinicalTrials.gov/show/NCT01143038 |
Completed |
Amgen |
2013-09-20 |
| NCT00774202 |
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP |
https://ClinicalTrials.gov/show/NCT00774202 |
Completed |
Weill Medical College of Cornell University |
2008-02-29 |
| NCT00770562 |
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00770562 |
Completed |
Hoffmann-La Roche |
2008-07-31 |
| NCT00749112 |
Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias |
https://ClinicalTrials.gov/show/NCT00749112 |
Completed |
Hospital Universitario Dr. Jose E. Gonzalez |
2010-08-31 |
| NCT00718692 |
Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00718692 |
Completed |
Symphogen A/S |
2011-08-31 |
| NCT00706342 |
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00706342 |
Completed |
Rigel Pharmaceuticals |
2010-04-30 |
| NCT00699140 |
Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT00699140 |
Completed |
Grifols Biologicals, LLC |
2013-12-31 |
| NCT00688272 |
Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag |
https://ClinicalTrials.gov/show/NCT00688272 |
Completed |
GlaxoSmithKline |
2008-09-25 |
| NCT00657410 |
Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT00657410 |
Completed |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2016-02-29 |
| NCT00625443 |
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 |
https://ClinicalTrials.gov/show/NCT00625443 |
Completed |
Eisai Inc. |
2009-06-30 |
| NCT00621894 |
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation |
https://ClinicalTrials.gov/show/NCT00621894 |
Completed |
GlaxoSmithKline |
2009-05-01 |
| NCT00603642 |
P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT00603642 |
Completed |
Amgen |
2009-04-13 |
| NCT00540423 |
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00540423 |
Completed |
GlaxoSmithKline |
2008-12-31 |
| NCT00515203 |
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects |
https://ClinicalTrials.gov/show/NCT00515203 |
Completed |
Amgen |
2009-03-31 |
| NCT00511147 |
IGIV Study for Chronic ITP Patients Ages 3-70 |
https://ClinicalTrials.gov/show/NCT00511147 |
Completed |
Grifols Biologicals, LLC |
2014-04-30 |
| NCT00508820 |
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP |
https://ClinicalTrials.gov/show/NCT00508820 |
Completed |
Amgen |
2011-01-01 |
| NCT00504075 |
A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00504075 |
Completed |
Bio Products Laboratory |
2011-08-31 |
| NCT00487968 |
Eltrombopag Taste Testing in Healthy Adult Volunteers |
https://ClinicalTrials.gov/show/NCT00487968 |
Completed |
GlaxoSmithKline |
NA |
| NCT00486421 |
Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT00486421 |
Completed |
Mayo Clinic |
2008-05-31 |
| NCT00475423 |
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. |
https://ClinicalTrials.gov/show/NCT00475423 |
Completed |
Hoffmann-La Roche |
2011-08-31 |
| NCT00467571 |
Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT00467571 |
Completed |
Mahidol University |
2008-09-30 |
| NCT00451594 |
High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP |
https://ClinicalTrials.gov/show/NCT00451594 |
Completed |
Cooperative Study Group A for Hematology |
2010-12-31 |
| NCT00442871 |
Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment |
https://ClinicalTrials.gov/show/NCT00442871 |
Completed |
GlaxoSmithKline |
2008-01-03 |
| NCT00441090 |
Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00441090 |
Completed |
Eisai Inc. |
2009-01-31 |
| NCT00426270 |
Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults |
https://ClinicalTrials.gov/show/NCT00426270 |
Completed |
Octapharma |
2008-09-30 |
| NCT00424177 |
Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) |
https://ClinicalTrials.gov/show/NCT00424177 |
Completed |
GlaxoSmithKline |
2008-08-31 |
| NCT00415532 |
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT00415532 |
Completed |
Amgen |
2008-11-07 |
| NCT00392951 |
Sirolimus for Autoimmune Disease of Blood Cells |
https://ClinicalTrials.gov/show/NCT00392951 |
Completed |
Children’s Hospital of Philadelphia |
2016-02-29 |
| NCT00376077 |
A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. |
https://ClinicalTrials.gov/show/NCT00376077 |
Completed |
The Hospital for Sick Children |
2016-03-31 |
| NCT00372892 |
Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00372892 |
Completed |
McMaster University |
2010-12-31 |
| NCT00370331 |
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag |
https://ClinicalTrials.gov/show/NCT00370331 |
Completed |
GlaxoSmithKline |
2008-07-31 |
| NCT00362349 |
Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients |
https://ClinicalTrials.gov/show/NCT00362349 |
Completed |
CSL Limited |
2008-10-31 |
| NCT00359463 |
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment |
https://ClinicalTrials.gov/show/NCT00359463 |
Completed |
GlaxoSmithKline |
2007-03-07 |
| NCT00351468 |
EXTEND (Eltrombopag Extended Dosing Study) |
https://ClinicalTrials.gov/show/NCT00351468 |
Completed |
Novartis |
2015-07-31 |
| NCT00344149 |
Rituximab as Second Line Treatment for ITP |
https://ClinicalTrials.gov/show/NCT00344149 |
Completed |
Ostfold Hospital Trust |
2014-03-31 |
| NCT00220727 |
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP |
https://ClinicalTrials.gov/show/NCT00220727 |
Completed |
Grifols Therapeutics LLC |
2003-10-31 |
| NCT00168038 |
Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10 |
https://ClinicalTrials.gov/show/NCT00168038 |
Completed |
CSL Behring |
NA |
| NCT00162006 |
Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT00162006 |
Completed |
Shire |
2003-12-01 |
| NCT00157079 |
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders |
https://ClinicalTrials.gov/show/NCT00157079 |
Completed |
Shire |
2003-12-16 |
| NCT00151840 |
Efficacy and Safety of IVIG-L in ITP Patients |
https://ClinicalTrials.gov/show/NCT00151840 |
Completed |
Sanquin Plasma Products BV |
NA |
| NCT00128882 |
Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D |
https://ClinicalTrials.gov/show/NCT00128882 |
Completed |
University of Aarhus |
2008-01-31 |
| NCT00117143 |
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00117143 |
Completed |
Amgen |
2004-07-19 |
| NCT00116688 |
Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00116688 |
Completed |
Amgen |
2010-01-31 |
| NCT00111475 |
Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00111475 |
Completed |
Amgen |
2004-06-17 |
| NCT00102739 |
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP) |
https://ClinicalTrials.gov/show/NCT00102739 |
Completed |
GlaxoSmithKline |
2007-01-31 |
| NCT00102336 |
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy |
https://ClinicalTrials.gov/show/NCT00102336 |
Completed |
Amgen |
2006-12-01 |
| NCT00102323 |
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy |
https://ClinicalTrials.gov/show/NCT00102323 |
Completed |
Amgen |
2006-09-01 |
| NCT00049725 |
Daclizumab to Treat Chronic Immune Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT00049725 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00002250 |
A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT00002250 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00005652 |
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura |
https://ClinicalTrials.gov/show/NCT00005652 |
Completed |
Office of Rare Diseases (ORD) |
2007-08-31 |
| NCT00001630 |
Treatment of Autoimmune Thrombocytopenia (AITP) |
https://ClinicalTrials.gov/show/NCT00001630 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |